Background: Renal dysfunction is a frequent and clinically relevant complication of cirrhosis, yet chronic kidney disease (CKD) often remains underrecognized, particularly in non-acute settings. Early identification of at-risk patients is essential to guide timely interventions. Although MELD, Child-Pugh Score (CPS), APRI, and FIB-4 are widely used to assess hepatic disease severity, their predictive value for advanced renal dysfunction is uncertain. Methods: In this retrospective cohort study (2014–2021, Klinikum Stuttgart), we evaluated the ability of MELD, CPS, APRI, and FIB-4 to predict severe renal dysfunction (chronic kidney disease [CKD] stage ≥ 3, according to Kidney Disease: Improving Global Outcomes [KDIGO] classification) in patients with alcoholic cirrhosis. Logistic and linear regression analyses were performed. In addition, machine learning (ML) models were trained to identify non-renal predictors of CKD stage ≥ 3. Results: Among 131 patients (mean age 62.8 ± 11.3 years; 71% male), 33% met criteria for KDIGO stage ≥ 3. MELD was significantly associated with advanced CKD (OR = 1.379, p < 0.001), with prevalence increasing from 17% (MELD ≤ 9) to 80% (MELD ≥ 20). CPS showed an inverse association (p = 0.002), while APRI and FIB-4 were not predictive. The optimized Random Forest model, refined through ROSE oversampling and feature selection, achieved an AUC of 0.757, with 76% accuracy, 82% sensitivity (KDIGO < 3), and 63% specificity (KDIGO ≥ 3). Conclusion: MELD was the most reliable conventional score for identifying advanced renal dysfunction in alcoholic cirrhosis. ML-based models incorporating routinely available clinical parameters further improved predictive performance and may support risk stratification in this high-risk population.
CKD-associated pruritus (CKD-aP) is a burden some symptom with incompletely understood pathophysiology and limited predialysis data. In this prospective observational study, 95 adult nondialysis CKD patients (stages G1-G5) were followed for up to 36 months (232 observations), 86 patients were analysed after exclusion of chronic dermatological conditions. Chronic pruritus (≥6 weeks) was assessed using a numerical rating scale (NRS) and anatomical mapping. Chronic pruritus occurred in 26 of 86 patients (30.2%), with numerically higher prevalence in advanced CKD (G3b-5 : 32.8% vs G1-3a: 22.7%), whereas intensity was numerically higher in early CKD (median 8 vs 5). The back, legs and head/ face were most frequently affected, consistent with the bilateral, nondermatomal pattern described in dialysis populations. Among patients with repeated assessments, 19.0% showed an episodic trajectory and 7.6% had persistent pruritus. Multivariable logistic regression and generalized estimating equations (GEE) were used to identify independent predictors of chronic pruritus. No laboratory parameter, including PTH, was independently associated with pruritus. Dyslipidaemia was the only clinical characteristic significantly associated with pruritus status (69.2% vs 43.3%, p=0.035). Given the modest sample size, smaller effect estimates may have been missed. CKD-aP affects approximately 1 in 3 predialysis patients, follows an episodic course, and is not explained by any single biochemical marker, supporting multifactorial pathophysiology.
Julian Müller-Kühnle, Christian Benignus, Severin Schricker, Moritz Schanz, Julia Todoroff, Jörg Latus, Wolfram Zoller, and Dominik Marschner. Int J Gastrointest Interv 2025;14:113-9. https://doi.org/10.18528/ijgii240059
Hepatorenal syndrome (HRS) is a life-threatening complication of advanced liver disease, associated with high short-term mortality and persistent symptom burden among survivors. While therapeutic advances have improved survival, little is known about the long-term quality of life (QoL), psychological distress, symptom management, and care preferences in this vulnerable population. In this prospective mixed-methods study, conducted between September 2024 and March 2025 at Robert Bosch Hospital in Stuttgart, Germany, patients who survived an HRS episode between 2019 and 2024 were identified retrospectively and invited for structured surveys. Patient-reported outcomes were assessed using the Short Form-12 (SF-12), targeted symptom and psychosocial questionnaires, and preference-oriented items. Quantitative data were analyzed descriptively and comparatively; open-ended responses were evaluated using qualitative content analysis. Fifteen HRS survivors (mean age 62 ± 13 years; 33% male; 73% with alcohol-related cirrhosis) participated. Mean scores on the physical component summary (PCS-12) and mental component summary (MCS-12) of the SF-12 were 42.6 ± 8.5 and 41.7 ± 7.4, respectively, indicating moderate impairment in physical and mental health. Fatigue (73%), fluid retention (53%), and dyspnea (47%) were the most frequently reported symptoms. Psychological distress was reported by 87% of patients, and 53% expressed substantial fear of rehospitalization. Treatment preferences varied: 53% favored intensive care in case of deterioration, 7% preferred a palliative approach, and 40% remained undecided. Survivors of HRS face considerable long-term impairments and psychosocial vulnerability. These findings underscore the need for structured multidisciplinary follow-up that integrates symptom relief, psychological support, and individualized decision-making. Given the exploratory nature and small sample size, further longitudinal studies are needed to confirm these findings and inform targeted supportive care strategies.